Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetRent ExpenseShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Alterity Therapeutics (ATHE) Non-Current Receivables (2016 - 2025)

Alterity Therapeutics has reported Non-Current Receivables over the past 5 years, most recently at $3.4 million for Q2 2019.

  • For Q2 2019, Non-Current Receivables rose 41.75% year-over-year to $3.4 million; the TTM value through Jun 2019 reached $3.4 million, up 41.75%, while the annual FY2019 figure was $3.4 million, 41.75% up from the prior year.
  • Non-Current Receivables for Q2 2019 was $3.4 million at Alterity Therapeutics, up from $4010.0 in the prior quarter.
  • Over five years, Non-Current Receivables peaked at $6.7 million in Q4 2015 and troughed at $2280.4 in Q2 2017.
  • A 5-year average of $1.7 million and a median of $1.1 million in 2017 define the central range for Non-Current Receivables.
  • On a YoY basis, Non-Current Receivables climbed as much as 104553.48% in 2018 and fell as far as 99.64% in 2018.
  • Year by year, Non-Current Receivables stood at $6.7 million in 2015, then crashed by 79.19% to $1.4 million in 2016, then fell by 19.62% to $1.1 million in 2017, then crashed by 99.64% to $4010.0 in 2018, then skyrocketed by 84263.16% to $3.4 million in 2019.
  • Business Quant data shows Non-Current Receivables for ATHE at $3.4 million in Q2 2019, $4010.0 in Q4 2018, and $2.4 million in Q2 2018.